Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASC4Kids asciminib dose and safety study in pediatric Ph+ CML-CP
jRCT2031210591Active, not recruiting
- Sponsor
- Novartis
- Start
- Jul 2022
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
01
Overview
Open-label trial of asciminib in chronic myelogenous leukemia (CML) (2 arms), sponsored by Novartis. Primary endpoints: AUClast and AUCtau. Started Jul 2022; status: active, not recruiting.
02
Drugs
asciminib
03
Conditions
chronic myelogenous leukemia (CML)
Beyond the preview
Go deeper on jRCT2031210591.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031210591.